Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD (XPLORE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03805100|
Recruitment Status : Completed
First Posted : January 15, 2019
Last Update Posted : March 14, 2022
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Macular Degeneration||Biological: Ranibizumab||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||582 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration|
|Actual Study Start Date :||April 19, 2019|
|Actual Primary Completion Date :||May 11, 2021|
|Actual Study Completion Date :||November 11, 2021|
Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
Active Comparator: Lucentis
Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
- Change in Best Corrected Visual Acuity (BCVA) [ Time Frame: Week 8 ]Change(s) in BCVA letters at Week 8 compared to baseline using the ETDRS protocol
- Change in Best Corrected Visual Acuity (BCVA) [ Time Frame: Week 4, 12, 16, 24, 36 and 52 ]Change in BCVA using the ETDRS protocol
- Change in total size of choroidal neovascular leakage area [ Time Frame: Week 24 and 52 ]Change in total size of choroidal neovascular leakage area measured by fluorescein angiography (FA)
- Change in total size of choroidal neovascularization [ Time Frame: Week 24 and 52 ]Change in total size of choroidal neovascularization measured by FA
- Change in Central Foveal Thickness (CFT) [ Time Frame: Week 2, 4, 8, 16, 24, 36 and 52 ]Change in Central Foveal Thickness (CFT) measured by OCT
- Percentage of subjects with loss of < 15 letters [ Time Frame: Week 4, 8, 24 and 52 ]Percentage of subjects with loss of < 15 letters using ETDRS
- Percentage of subjects with a gain of ≥ 15 letters [ Time Frame: Week 4, 8, 24 and 52 ]Percentage of subjects with a gain of ≥ 15 letters using ETDRS
- Intra- or subretinal fluid [ Time Frame: Week 24 and 52 ]Number of subjects without intra- or subretinal fluid (ie, completely dry)
- Retinal pigment epithelium detachments [ Time Frame: Through study completion ]Number of subjects with retinal pigment epithelium detachments
- Systemic Ranibizumab concentrations [ Time Frame: Day 0, Day 1 and week 20 ]Systemic Ranibizumab concentrations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||50 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Written and signed informed consent form obtained at screening, before any study-related procedures.
- Willingness and ability to undertake all scheduled visits and assessments as judged by the investigator.
Newly diagnosed, active subfoveal Choroidal Neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD) in the study eye. Note: Active CNV indicates the presence of leakage as evidenced by Fluorescein Angiography (FA) and intra- or subretinal fluid as evidenced by Optical Coherence Tomography (OCT) which must be confirmed by the central reading center during Screening:
- The area of CNV must be ≥ 50% of the total lesion area in the study eye, and
- Total lesion area ≤ 9.0 Disc Areas (DA) in size (including blood, scars and neovascularization) as assessed by FA in the study eye.
- Best Corrected Visual Acuity (BCVA) of ≤ 73 and ≥ 49 ETDRS letter score in the study eye, using ETDRS chart (20/40 to 20/100 Snellen equivalent) at Screening.
- Fellow eye should not be expected to need any anti-VEGF treatment for the duration of study participation.
- Age ≥ 50 years at screening.
- Male and female subjects of childbearing potential must be willing to completely abstain or agree to use an appropriate method of contraception, from the time of signing informed consent and for the duration of study participation through 3 months, following the last dose of study drug.
- Any previous intervention including pharmacological treatment, laser and/or surgery for wAMD in either eye; (Exception: Vitamin supplementation for AMD prevention).
- Any previous vitreoretinal surgery in the study eye for any cause.
- Any previous IVT treatment including any anti-VEGF medications, steroids and/or any other investigational medication in either eye.
- The use of long-acting steroids, either systemic or intraocular in any eye, in the 18 months before planned initiation of study treatment. (Note: Iluvien® [fluocinolone acetonide intravitreal], current or planned implantation during the study, is prohibited.)
- Subfoveal fibrosis, atrophy or scarring extending > 50% of total lesion area, in the study eye as assessed by the investigator at screening and confirmed by the central reading center prior to randomization.
- Choroidal neovascularization in either eye due to non-AMD causes (eg, DME, RVO, ocular histoplasmosis or trauma, etc.) as assessed by FA and confirmed by central reading center.
- Active or recent (within 28 days prior to randomization) intraocular, extraocular, and periocular inflammation or infection in either eye.
- History of idiopathic or autoimmune-associated uveitis in either eye.
- Infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye.
- Unmedicated intraocular pressure (IOP) ≥ 30 mmHg at Screening in either eye.
- Topical ocular corticosteroids administered for ≥ 30 consecutive days in the study eye within 90 days prior to Screening.
- Spherical equivalent of the refractive error in the study eye demonstrating more than 8 diopters of myopia.
- Corneal transplant or corneal dystrophy in the study eye.
- History of rhegmatogenous retinal detachment in the study eye.
- History of macular hole in the study eye.
- Retinal pigment epithelial tear or rip, involving the macula in the study eye as assessed by FA and confirmed by the central reading center.
- Current vitreous hemorrhage in the study eye.
- Subretinal hemorrhage that is ≥ 50% of the total lesion area in the study eye, or if the subretinal hemorrhage involves the fovea is 1 or more DA (≥ 2.54 mm2) in size in the study eye, as assessed by FA and confirmed by the central reading center.
- Other intraocular surgery (including cataract surgery) in the study eye within the 3 months prior to baseline. The yttrium aluminum garnet [YAG] posterior capsulotomy is allowed not later than 4 weeks prior to screening.
- Any concurrent intraocular condition in the study eye (eg, cataract or diabetic retinopathy) that, in the opinion of the investigator, could require treatment during the study period to prevent or treat loss of visual acuity.
- Significant media opacities (including cataract) in the study eye interfering with BCVA assessment or fundus imaging (FA/FP/OCT).
- Aphakia or absence of the posterior capsule in the study eye, unless it occurred as a result of a YAG posterior capsulotomy in association with prior posterior chamber intraocular lens implantation.
- Presence of advanced glaucoma or optic neuropathy that involve(s) or threaten(s) the central visual field in the study eye (as judged by the investigator).
- History of glaucoma filtering surgery or argon laser trabeculoplasty in the study eye (Exception: Laser iridotomy and selective laser trabeculoplasty are allowed).
- Uncontrolled ocular glaucoma or hypertension in the study eye, defined as IOP ≥ 25 mmHg despite treatment with anti-glaucoma medication.
- Any previous systemic anti-VEGF treatment (eg, bevacizumab).
- Contraindication for Lucentis® (hypersensitivity to ranibizumab or to any of the study treatment excipients).
- Current treatment for active systemic infection.
- Females who are pregnant, nursing, planning a pregnancy during the study, or of childbearing potential and not using a reliable method of contraception and/or not willing to use a reliable method of contraception during their participation in the study.
- Participation in another clinical trial within the previous 3 months or any other clinical trial of anti-angiogenic drugs.
- Reasonable suspicion of other disease or condition that might render the subject at a high risk of treatment complications or otherwise confound interpretation of the study results (as judged by the investigator).
- PK subgroup only: Contraindication for additional blood sampling (as judged by the investigator).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03805100
|Principal Investigator:||Anat Loewenstein, Professor||Tel-Aviv Sourasky Medical Center|
|Responsible Party:||Xbrane Biopharma AB|
|Other Study ID Numbers:||
|First Posted:||January 15, 2019 Key Record Dates|
|Last Update Posted:||March 14, 2022|
|Last Verified:||March 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Angiogenesis Modulating Agents
Physiological Effects of Drugs